Document Detail

The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD).
MedLine Citation:
PMID:  21817841     Owner:  NLM     Status:  In-Data-Review    
The usefulness of ezetimibe was examined in 297 patients with dyslipidemia who did not achieve LDL-C target levels set in JAS 2007 Guidelines by lifestyle modification. The mean period of administration was 178.2±295.4 days. Ezetimibe significantly improved serum lipid levels in the patients with and without non-alcoholic fatty liver disease (NAFLD) (p<0.01). Significant improvement of AST, ALT and γ GTP levels were also observed in the patients with NAFLD (p<0.01, p<0.05, and p<0.01, respectively). Seventy of the patients with NAFLD who underwent abdominal ultrasound before and after administration of ezetimibe were followed. Of those, 38.6% of the patients showed disappearance of steatosis, indicating that administration of ezetimibe is useful in patients with NAFLD.
Tadashi Shiwa; Yoshiya Kawanami; Tomoko Yokoyama; Akihiko Moritani; Masatoshi Hashimoto; Tohru Gotoh
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology     Volume:  108     ISSN:  1349-7693     ISO Abbreviation:  Nihon Shokakibyo Gakkai Zasshi     Publication Date:  2011  
Date Detail:
Created Date:  2011-08-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2984683R     Medline TA:  Nihon Shokakibyo Gakkai Zasshi     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1383-92     Citation Subset:  IM    
Department of Internal Medicine, Fuji Film Health Care Center.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic and Adverse Effects of Flunixin-Meglumine in Adult and Young Cats.
Next Document:  A case of candidal infection of gastric ulcers with characteristic endoscopic findings.